More Stories

Informist, Friday, Oct. 03, 2025

MUMBAI – Nifty Pharma index is expected to move in a range with a positive bias, according to analysts. Positive sentiment in the market will be supported by factors such as 100% pharma tariffs being put on hold by the US administration and a deal between global pharmaceutical major Pfizer and the US government. 

The deal between Pfizer and US administration to cut drug prices for some of its products sold in the Medicaid channel has brought a sigh of relief to the pharma sector. In exchange for tariff relief for three years, Pfizer will participate in the government's direct-to-consumer website, cutting prices for new drugs. This move is expected to provide some relief from pharmaceutical tariffs in the uncertain environment, as more companies are now likely to approach the US administration to negotiate a deal. 

Most Indian drug makers don't have much exposure to the branded or patented drug segment in the US, the delay of 100% tariff for these products might not move a needle regarding uncertainities around exports to the US market, an analyst at a domestic brokerage said. However, Sun Pharmaceutical Industries, with its 13-15% exposure to US innovative drugs, is likely to face tariffs as it manufactures its key drugs outside the US. The company's largest drug, Ilumya, is manufactured in South Korea and Europe, generating revenue from government channels like Medicare Part B and Medicaid, according to a report by Nuvama Institutional Equities. Signing a similar deal or taking an initiative to manufacture in the US could help Sun Pharma avoid tariffs in the near term.

The Nifty Pharma index is likely to move in a broad range of 21300-22800 points and the index is likely to find immediate support at 21300 levels and encounter resistance between 22000-22200 points, according to Vipin Kumar, technical and derivatives analyst at Globe Capital market. For the week ended Friday, the Nifty Pharma index ended 1.2% higher at 21756.35. Wockhardt rose over 9% throughout the week and it was the biggest gainer in the index. On the other hand, IPCA Laboratories was the biggest loser falling over 4%.  

TOP HEADLINES

* HC bars Brinton Pharma from using name similar to Mankind Pharma's AcneStar
* PRESS: Amid govt shutdown, US puts 100% tariff on pharma import on hold
* Biocon board OKs early full redemption of INR 10.70-bln NCDs
* Zydus Life arm gets US FDA Complete Response Letter for Menkes drug CUTX-101
* IPO Alert: Sai Parenteral's files DRHP for fresh issue of INR 2.85 bln, OFS
* Lupin launches blood clot drug generic Rivaroxaban in US
* Jubilant Biosys allots shares worth INR 5.16 bln to Jubilant Pharmova
* New World Fund sells 2.02% stake in Max Healthcare via open mkt transaction
* Biocon Biologics settles Bosaya, Aukelso biosimilars patent case with Amgen
* Wockhardt submits new drug application to US FDA for Zidebactam-Cefepime
* Lupin gets approval from US FDA for Rivaroxaban for oral suspension
* IPO Alert: Virupaksha Organics files draft papers with SEBI for fresh issue
* Trade min moots anti-dumping duty on resorcinol from China, Japan for 5 yrs
* HC refuses to bar AET Lab on drug for chemotherapy-induced nausea, vomiting
* Lupin's Netherlands arm to acquire VISUfarma BV for 190 mln euros
* Syngene Intl says Bengaluru income tax dept has cut demand to INR 1.04 bln
* Biocon board to Wednesday consider early redemption of NCDs
* HSBC Global sees headline risk to Sun Pharma from tariff, some hit on revenue
* Alkem Lab to transfer trade generics business to arm effective Oct 1

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

Reported by P. Madhu Kumar

Edited by Deepshikha Bhardwaj

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.